monoclonal antibody targeting the programmed death 1 (PD-1) receptor. In early studies, treatment with pembrolizumab led to dramatic and durable responses in select patients with higher levels of PD-L1 expression. This remarkable efficacy lead to approval of pembrolizumab in the second-line setting as response rates were almost doubled compared to standard of care (SOC) chemotherapy. 3 More recently, data in the first-line setting from the KEYNOTE-024 study have redefined the SOC therapy for a selected subset of patients. In patients whose tumors have 50% PD-L1 expression by IHC staining, pembrolizumab had a clear progression-free survival (PFS) and overall survival (OS)
benefit. 4 A recent meta-analysis evaluated the correlation between PD-L1 expression and outcomes with the use of PD-L1 inhibition and supported the idea that treatment with PD-1 inhibition such as pembrolizumab was more beneficial with higher levels of PD-L1 expression. 5 The current evaluation of PD-L1 expression for pembrolizumab is an immunohistochemistry assay, using the PD-L1 IHC 22C3 assay (Dako North and Dako 28-8), there is some evidence suggesting that results from one platform may correlate with those from another platform. 6 The majority of patients with lung cancer continue to be diagnosed at an advanced stage for which broad molecular profiling is recommended and, in an era in which small volume or cytology specimens have become the main diagnostic modality for most patients with lung cancer, it would be advantageous to be able to utilize these small specimens for PD-L1 testing. The National Comprehensive Cancer Network (NCCN) 2017 Clinical Practice Guidelines for Nonsmall Cell Lung Cancer (NSCLC) recommend utilization of a procedure that allows concurrent diagnosis, staging and procurement of material, which is sufficient for genetic testing. 7 As such guidelines recommend endobronchial ultrasound-guided transbronchial needle aspiration (EBUS TBNA) as the principal test for the diagnosis and staging of lung cancer. 8 Several studies to date have shown suitableness of formalin-fixed, paraffin-embedded (FFPE) cell-block samples for NGS testing obtained by EBUS TBNA 9, 10 and that cytology smear preservation methods provide quality DNA for testing. 11, 12 However, there are no reports on performance, utility and satisfactory results of cytology specimen obtained by EBUS TBNA for PD-L1 testing in addition to NGS for advanced NSCLC.
Our study describes handling of cytology specimens procured by EBUS TBNA at our institution and reports the satisfactory results of PD-L1, next generation sequencing (NGS), and anaplastic lymphoma kinase (ALK) fusion gene FISH testing with cytology specimens obtained by EBUS TBNA.
| M E TH ODS AN D M A TER I A LS
The study was a retrospective chart review study approved by IRB at University of Florida # IRB201701393 as exempt.
| EBUS TBNA tissue sampling
A standardized examination of the interlobar, hilar, and mediastinal lymph nodes is employed. If EBUS identifies a lymph node >5 mm, then a 22-gauge needle EBUS TBNA of the lymph node is performed.
A routine EBUS-TBNA procedure results in the acquisition of at least three aspirates from each lymph node. During the initial sample aspiration, the biopsy needle is removed from the bronchoscope and a single drop of sample material is deposited onto a labeled glass slide.
The sample is delivered first by advancing the stylet through the needle channel and, if it results in an insufficient discharge of material, this is followed by the attachment of an empty 10 cc syringe to the stylet hub and flushing of air through the channel. After material is expelled onto the glass slide, a second slide is used to smear the sam- 
| Specimen handling
The air-dried slides for immediate assessment were stained with DiffQuik (Siemens Healthcare Diagnostics Inc, Deerfield, Illinois). The slides fixed in alcohol were stained with routine Papanicolaou stain. The cellblock preparation was as follows: After centrifugation of the original specimen, the supernatant was decanted under a hood. If the pellet was clear, the pellet was stained with EA65 stain (Sigma-Aldrich, Saint
Louis, Missouri). Three drops of plasma were added using a pipette;
and then one scoop (microspatula) of lyophilized thrombin (SigmaAldrich, Saint Louis, Missouri) was added. The sample was stirred and then allowed to clot. The clot was teased out onto lens paper. At this point, the cell-block was processed routinely as FFPE tissue. Sections from the FFPE tissue were cut at 4 lm thickness; five sections were produced. The first and the fifth sections were stained with routine hematoxylin and eosin (H&E). Four intervening slides were used for routine IHC stains, such as p40, Napsin-A, thyroid transcription factor-1 and cykeratin 5/6, for tumor typing (not shown in this study). The H&E stained slides from each specimen were reviewed by a pathologist.
If tumor was found, only specimens with a minimum of 100 viable tumor cells were considered adequate for PD-L1 IHC 6 and for other ancillary tests. Specimens that did not have 100 viable cells could not be tested for PDL1 but were considered for NGS, ALK, 
| Satisfactory results for NGS, ALK FISH, and PD-L1 IHC
Of the 50 patients reviewed, four (8%) patients had an insufficient number of tumor cells in the block to perform any of the ancillary testing. Forty-one (82%) patients had an adequate sample for all three ancillary testing including NGS, ALK FISH gene rearrangement, and PD-L1 expression. Three (6%) patients were tested for NGS and ALK FISH but not for PD-L1 testing. One (2%) patient was tested for PD-L1 only, and one (2%) patient was tested only for NGS and PD-L1, both at the provider's discretion. Table 2 summarizes the satisfactory results of EBUS TBNA for ancillary testing.
| PD-L1 results
Of the 43 patients in whom PD-L1 expression assay could be performed successfully, 14 (32%) patients had levels of PD-L1 expression expression from EBUS TBNA samples was around 90%. As mentioned above, in three patients NGS and ALK FISH testing could be performed successfully but not PD-L1 expression. In two of these three patients, PD-L1 testing could not be performed reliably due to high background staining of immune cells that were present in the blood component of the specimen despite of having sufficient cellularity in the block (at least 100 viable tumor cells). 6 Thus, looking from adequacy of sample and cellularity of the block, this study shows that 45 (90%) patients had enough cellularity in the block to effectively test for PD-L1
expression.
Thirty two percent of our patients had PD-L1 expression of >50%, which is similar to what has been described in the literature for advanced NSCLC. The sites sampled in our study including the hilar and mediastinal nodes are the ones, which are commonly accessed by trained pulmonologists on a routine basis. An average of 6 passes from a particular site was required to have an adequate cell-block for all three ancillary tests in our experience. As has been previously described in the literature, EBUS TBNA is a very safe procedure 13 and the IHC analysis is perfectly controlled, managed and standardized, it could be considered that PD-L1 results from cell-block testing should be similar to those of the histological specimen. Some of the limitations of our study include a small sample size, retrospective analysis, and a single center experience which may not be reproducible at other centers.
In conclusion, EBUS TBNA can be successfully used to test for PD-L1 expression on tumor cells with high satisfactory results and minimal complications. Our study demonstrates that cell-block obtained from EBUS TBNA can provide adequate material not only for diagnosis and morphological typing of lung cancer using IHC but also for several ancillary tests including NGS, ALK rearrangement by FISH, and PD-L1
IHC expression all from the same specimen. Further studies will be needed to replicate our institutional experience and demonstrate concordance between histology and cytology specimens. 
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